CD274 and cancer: PD-1 suppresses the anti-cancer immune activity of T cells through its interaction with ligands PD-L1 or PD-L2 (15, 16), leading to downregulation of the T cell receptor and subsequent inhibition of T cell activation and cytokine release (17, 18).